HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin Devices, ‘Hair-ceuticals’ Are Opportunities For Firms That Avoid Pitfalls

This article was originally published in The Rose Sheet

Executive Summary

Growth opportunities exist for firms marketing home-use skin-care devices and cosmeceuticals in new categories such as hair care, but such products also can invite regulatory scrutiny for exceeding FDA’s definition of a cosmetic. Consulting with FDA on a premarket basis and crafting claims with attention to regulatory parameters can help firms stay in the agency’s good graces.

You may also be interested in...



P&G’s NIOXIN Shows How To Address Hair Loss Without An FDA Warning

With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.

Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits. Widely credited as a pioneer that helped create the cosmeceutical category, Strivectin has been warning-free since 2005 when FDA came down on its “Better than Botox?” positioning.

Lauder Looks to Bring Clinique, Estee Lauder To ‘Full Speed’ In H2

Identifying its luxury and makeup artistry brands as second-quarter growth drivers, the Estee Lauder Companies says it will put more resources behind its core Estee Lauder and Clinique brands in the second half of fiscal 2015. The firm’s sales for the quarter inched up 1% on a reported basis to $3.04 billion.

Related Content

Related Companies

UsernamePublicRestriction

Register

RS019785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel